Traumatic brain injury (TBI) is a leading cause of long-term disability in the United States. Even in comparatively mild injuries, cognitive and behavioral symptoms can persist for years, and there are currently no established strategies for mitigating symptoms in chronic injury. A key feature of TBI-induced damage in acute and chronic injury is disruption of metabolic pathways. As neurotransmission, and therefore cognition, are highly dependent on the supply of energy, we hypothesized that modulating metabolic activity could help restore behavioral performance even when treatment was initiated weeks after TBI. We treated rats with pioglitazone, a FDA-approved drug for diabetes, beginning 46 days after lateral fluid percussion injury and tested working memory performance in the radial arm maze (RAM) after 14 days of treatment. Pioglitazone treated TBI rats performed significantly better in the RAM test than untreated TBI rats, and similarly to control animals. While hexokinase activity in hippocampus was increased by pioglitazone treatment, there was no upregulation of either the neuronal glucose transporter or hexokinase enzyme expression. Expression of glial markers GFAP and Iba-1 were also not influenced by pioglitazone treatment. These studies suggest that targeting brain metabolism, in particular hippocampal metabolism, may be effective in alleviating cognitive symptoms in chronic TBI.
Introduction
Traumatic brain injury (TBI) is a significant source of long-term disability in people under 45 years of age, affecting approximately 2.8 million people in the United States every year (Faul and Coronado, 2015) . Even in injuries diagnosed as mild, > 20% of patients experience cognitive and behavioral symptoms that prevent a full return to previous activities (Benedictus et al., 2010) .These deficits can persist for the remainder of the patient's lifetime and there is currently no consensus on effective treatment for these patients (Ponsford et al., 2014) .
TBI is an ongoing process with distinct phases (Faul et al., 2010) . The primary injury is a direct result of mechanical forces applied to the brain that cause direct physical damage to cells and axon tracts (Davis, 2000) . Secondary injury is more prolonged and widespread, involving pathophysiological sequences of events including cascades of glial cytokine release, altered metabolic function, and changes in synaptic transmission and plasticity (Raghupathi, 2004) . Targeting secondary injury cascades provides the best opportunity for successful treatment of post-TBI symptoms, however the progression of secondary damage processes over time are complex and poorly understood.
Energy metabolism is intimately linked to cognition. The brain has a high energetic demand relative to its size, consuming about 20% of the body's resting metabolic output (Aiello and Bach-y-Rita, 2000) . The vast majority of the brain's energy consumption goes to supporting the electrochemical gradients across cell membranes that are required for neurotransmission underlying cognition (Aiello and Bach-y-Rita, 2000; Shetty et al., 2012) . Increasing the brain's supply of energetic substrates either through direct infusion (Ragozzino et al., 1998) or through systemic administration (Moro et al., 2011; Brabazon et al., 2017) transiently improves working memory and executive function in rodents and humans (Brabazon et al., 2017;  https://doi.org/10.1016/j.nbd.2019.104611 Received 28 February 2019; Received in revised form 2 September 2019; Accepted 6 September 2019 . Conversely, impaired energy metabolism precedes cognitive decline in multiple chronic neurodegenerative disorders (Yin et al., 2016; Varatharajah et al., 2019) . We hypothesized that similar metabolic impairments exist in chronic TBI reducing the capacity for energy production in response to neural activity. We additionally hypothesized that compounds targeting energy metabolism and mitochondrial function would improve cognitive deficits after TBI.
While the acute effects of TBI on energy metabolism are well-established (Bowman et al., 2019; Shijo et al., 2017; Bartnik-Olson et al., 2013) , the extent to which these early changes are consolidated in chronic injury is less well understood. Mitochondrial deficits are still evident in both cortex and hippocampus a month after closed-head experimental TBI (Lyons et al., 2018) . Expression patterns of genes related to glucose and lactate metabolism are also not completely restored one month after controlled cortical injury (Zhou et al., 2017) . In a rat lateral fluid percussion injury, we found differences between control and TBI animals 2 months after injury that suggested energy, amino acid, and neurotransmitter metabolism was not fully recovered (McGuire et al., 2018) .
Here, we hypothesized 1) deficits in glucose metabolism after TBI were not recovered within the two month time frame we were examining, 2) increasing cellular energy metabolism would improve the deficits in working memory we find in our chronic TBI model, and 3) treatment need not be initiated early after injury at acute or subacute time points, but could be effective at chronic time points as well. We administered the FDA-approved diabetes drug pioglitazone to rats beginning 46 days after TBI, and tested working memory after 14 days of treatment in the radial arm maze. Pioglitazone readily crosses the blood brain barrier with oral administration (Grommes et al., 2013) , and was shown to improve behavioral and functional deficits in acute models of brain and spine injury (Sauerbeck et al., 2011; Patel et al., 2017; McTigue et al., 2007) . Pioglitazone is also being tested as a potential therapeutic agent in models of chronic neurodegenerative disease (Cippitelli et al., 2017; Liu et al., 2015) . Our primary goals were to determine whether initiating pioglitazone treatment in chronic TBI would alleviate working memory impairments and/or upregulate glucose metabolism in regions of the brain critical to learning and memory.
Pioglitazone is an agonist of peroxisome proliferator-activated receptors (PPARs), nuclear receptors that are master regulators of genes involved in carbohydrate and fat metabolism. However, pioglitazone also has PPAR-independent and anti-inflammatory effects on monocytes and microglia (Sauerbeck et al., 2011; Breidert et al., 2002) . Thus, the mechanism for pioglitazone's neuroprotective effects are not well established. We expected that hexokinase protein and enzyme activity would be reduced in the hippocampus and frontal cortex of chronically injured animals and that pioglitazone treatment would upregulate expression of PPARγ-coactivating protein (PGC1a), a transcription factor downstream of PPARs, upregulate hexokinase expression and activity, and potentially reduce signs of astrogliosis. We found that pioglitazone treatment increased hexokinase activity in the hippocampus, and that working memory performance in the radial arm maze was significantly better in treated TBI rats than untreated TBI animals. These findings provide evidence that the window of opportunity for treating cognitive symptoms after injury is not limited to the initial days or weeks after TBI and that targeting energy metabolism may be a strategy for improving cognitive deficits after injury.
Methods

Subjects
We used thirty adult male Sprague Dawley rats (250-275 g) obtained from Envigo (Indianapolis, IN) in this study. The animals were pair housed with ad libitum access to food and water. The number of animals required for the study was calculated from a pilot study of TBI (n = 7) and sham animals (n = 7) in the radial arm maze test used in the current study ( Supplementary Fig. S1 ). Based on group means of 4.1 errors for TBI and 1.7 errors for sham with a pooled standard deviation of 1.6, 10 animals were determined to be sufficient to detect behavioral differences for 3 pairwise comparisons at a power of 0.80. All procedures using animals were reviewed and approved by the University of Cincinnati Institutional Animal Care and Use Committee.
Lateral fluid percussion injury
Lateral fluid percussion injury was performed as previously described (McGuire et al., 2018) . Briefly, isoflurane anaesthetized rats received a 4.8 mm craniotomy located 4 mm posterior to bregma and 2.5 mm lateral to the sagittal suture over the right parietal cortex. A plastic hub was attached to the skull surrounding the craniotomy using cyanoacrylate glue and surgical cement. Approximately 72 h after the craniotomy, animals were assigned to either sham (surgical control) or TBI in a 1:2 ratio. TBI animals were connected directly to the lateral fluid percussion instrument and a sterile saline pulse was applied to the dura at a force of approximately 2 atm (mean 2.07, range 1.84-2.45). Sham animals underwent the same surgical protocol, but no fluid pulse was administered. Injury severity was assessed by reflex righting time (RRT), the time the rat required to return to upright from a supine position following TBI. The duration of unconsciousness provides an approximation of injury severity and is widely used across multiple models of rodent TBI (Rodriguez et al., 2019) (Learoyd and Lifshitz, 2012) . The rats were re-anaesthetized briefly to close the incision and then allowed to recover. Animals were housed individually and monitored daily for seven days before being returned to pair-housing for the remainder of the study. One animal in the TBI group was excluded due to a righting time of < 2 min, which indicated they did not receive an appropriate injury. Final group sizes were sham n = 10 and TBI n = 19.
Behavioral testing
Prior to craniotomy, animals were acclimated to the food rewards used during behavioral testing. Animals were pre-tested in the open field in order to assess baseline locomotor activity. We utilized an eightarm radial arm maze (RAM) working memory task to determine eligibility for the study. The animals were habituated to the maze for fifteen minutes on two consecutive days. All 8 arms were baited during habituation to encourage exploration of the entire maze. The third day, the maze was not baited and the animals were required to visit seven out of eight total arms within 10 min. Revisiting a previously explored arm was counted as an error. Once the animal entered all eight arms the test was ended. Animals that made 5 or more errors in the pre-surgical evaluation were not considered for the study.
On day 54 post-injury, animals were tested a second time in the open field to determine whether there were changes in locomotor activity from baseline. The radial arm maze test was conducted on day 58-60 post-TBI with 2 days of habituation to the baited maze followed by the working memory test. As with the pre-surgery testing, the animals were required to visit 7 of the 8 arms and returning to previously explored arms was scored as an error.
Drug administration
These studies used a 20 mg/kg/day oral dosing strategy and administered pioglitazone daily for 14 days. On day 45 post-injury, TBI animals were randomly assigned to a control or drug group. Final group sizes were n = 10 Sham, n = 10 TBI + vehicle, n = 9 TBI + pioglitazone. Pioglitazone was administered orally in chocolateflavored treat pellets (4.25 mg pioglitazone/1 g pellet; Bio-Serv, Flemington, NJ). Animals in the control groups received identical pellets without added pioglitazone. Each animal was removed from their home cage, placed into a clean holding cage with two drug or drug-free pellets and monitored until both pellets were completely consumed before being returned to their home cage. All animals received drugfree chocolate-flavored pellets from day 39 post-injury to day 45 postinjury in order to habituate the animals to the pellets and the drug administration protocol. From day 46 through day 60 post-injury, animals received two drug-free or drug pellets in accordance with their group assignment. Animal weights were recorded daily in order to calculate exact doses.
Tissue collection
On day 61 post-injury, rats were sacrificed via rapid decapitation and their brains were immediately dissected into left and right hemispheres. The frontal cortex and hippocampus were dissected on wet ice from the right (ipsilateral) hemisphere (McGuire et al., 2018) . Frontal cortex was collected by removing the olfactory bulb and cutting just rostral to the corpus callosum. Hippocampus was removed by gently removing the midbrain and thalamus to expose the hippocampus. The entire hippocampus was then peeled away from the underlying cortex (EJNeuroscience, 2014). The tissue samples were immediately snap frozen on dry ice and stored at -80C°.
Western blotting
Homogenized samples from hippocampus and frontal cortex were quantified via BCA assay. 7.5-12 μg of total protein was loaded into 4-15% Mini-PROTEAN TGX precast gels (#4561086 Bio-Rad, Hercules, CA, USA). Gels were run at 200 Mv and transferred at 20Mv in a BioRad semi-dry transfer system. Membranes were blocked for 1 h and incubated overnight at 4°C in primary antibody. Primary antibodies were mouse anti-HK1 (1:1000, #sc-46,695 Santa Cruz Biotechnology. Santa Cruz, CA), rabbit anti-PGC1a (1:1000 NBP1-04676 Novus Bio, St Louis, MO) rabbit anti-Glut1 (1:1000 NB110-39113 Novus Bio, St Louis, MO), rabbit anti-Glut3 (1:1000 ARP76597 AVIVA Systems Biotechnology, San Diego, CA), rabbit anti-GFAP (1:1000, 12389S Cell Signaling Technologies, Danvers, MA), mouse anti-IBA-1 (1:1000, NB100-1028 Novus Bio, St Louis, MO), rabbit anti-β-Tubulin (1:3000, #2146S Cell Signaling Technologies, Danvers, MA). The membranes were then probed with species-appropriate IRDYE secondary antibodies, donkey anti-mouse 800CW (1:20,000, #925-32212 LI-COR Biosciences, Lincoln, NE) and donkey anti-rabbit 680RD (1:10,000, #925-32213 LI-COR Biosciences, Lincoln, NE). The membranes were visualized using a LI-COR Odyssey Imager and analyzed using ImageStudio.
Hexokinase activity
Hexokinase activity was measured using a colormetric hexokinase activity kit (BioVision, Milpitas, CA) according to the manufacturer's instructions. 20 μg of total protein was loaded per well, and background enzyme activity was measured for each sample. Background activity was subtracted from the total activity of each sample prior to further analyses. Samples were run in duplicate. Concentrations of the reaction product NADH was calculated for each sample from the standard curve. Absorbance measurements were taken every 5 min over 2 h. Data was analyzed over 90 min, within the linear range of NADH accumulation. Samples that failed to show consistent increase in reaction product over time were excluded from analyses. Assay specificity was determined using 50 mM of the hexokinase inhibitor lonidamine (R&D biosystems, Minneapolis, MN) in pooled samples.
Statistical analyses
Analyses were performed using Graphpad Prism 7.0 (Graphpad Software, San Diego, CA) and R 3.6.1. Data were tested for normality using the D'Angostino and Pearson and Shapiro-Wilkes normality tests. Outliers were detected using Robust regression and Outlier removal (ROUT) with Q set to 1%, meaning that the test has a false discovery rate of 1% (Motulsky and Brown, 2006) . Statistical outliers were excluded from analysis. Final subject numbers for each experiment are included in the figure legends. Comparisons between group means were analyzed by one-way ANOVA with Tukey's post hoc comparisons when appropriate, by Kruskal-Wallis test for data with non-Gaussian distribution, or by unpaired t-Test for side by side comparisons. Hexokinase activity was analyzed by repeated measures ANOVA for accumulation of NADH over time. Effect size for ANOVA, omega squared (ω 2 ), was calculated in R version 3.6.1 using the omega.F function in the MOTE package (Buchanan et al., 2019) . We selected ω 2 over the more common eta squared (η 2 ) as it is less biased with small samples sizes (Lakens, 2013) . We interpreted the effect size for ω 2 as: no effect (ω 2 < 0.01), small effect (ω 2 < 0.06), moderate effect (ω 2 < 0.14), and large effect (ω 2 ≥ 0.14) as originally proposed by Cohen (Cohen, 2013) .
Results
Subjects
There was a significant effect of treatment on reflex righting time (RRT) (ω 2 = 0.600; p < 0.0001). RRT was significantly shorter in sham animals than in either TBI no drug (TBI) (p < 0.0001) or TBI+ pioglitazone (TBI + pio) (p = 0.0003) ( Fig. 1a ). There was no difference in RRT between TBI animals later assigned to vehicle or pioglitazone (unpaired t-Test, t = 1.479, p = 0.182) ( Fig. 1a ). There was a moderate effect of treatment group on the amount of weight gained over the course of the study between the three subject groups which was not statistically significant (ω 2 = 0.07; p = 0.150) (Fig. 1b) . The calculated dose of pioglitazone based on body weight in the drug treated rats was 21.7 +/− 3.55 mg/kg. Fig. 1 . a. Reflex righting time was significantly longer in animals the TBI than in sham animals (ω 2 = 0.0.600, p < 0.0001). Post-hoc analysis found no difference in righting time between TBI groups. b. There was minimal effect of treatment on weight gained over the course of the study (ω 2 = 0.070, p = 0.150). n = 10 sham, n = 10 TBI, and n = 9 TBI + pio. Data is mean +/− SEM. * = p < 0.05.
Chronic deficits in working memory performance but not locomotor activity
We used a radial arm maze (RAM) task to evaluate working memory in chronic TBI and the open field to identify any differences in locomotor activity that could confound interpretation of the RAM results. Post-hoc analyses identified no differences between groups at baseline in distance travelled in the open field (ω 2 = 0.040, p = 0.247) or in RAM performance (ω 2 = −0.04; p = 0.667)(data not shown). There was a small effect of treatment on distance travelled in the open field that was not statistically significant (ω 2 = 0.020; p = 0.302) on day 54 after TBI (Fig. 2a ). We found a large effect of treatment on RAM performance (ω 2 = 0.23; p = 0.011), and that TBI animals made more errors in in the RAM relative to sham (p = 0.018) and TBI + pio (p = 0.036) groups (Fig. 2b) . We found no differences in the errors committed between sham and TBI + pio (p = 0.972) (Fig. 2b) .
Pioglitazone does not decrease expression of astroglial or microglial markers in chronic TBI
Performance on the radial arm maze requires the engagement of frontal cortex and hippocampus in both rodents (Kolb et al., 1983; Shanmugasundaram et al., 2015) and humans (Astur et al., 2005) . For this reason, we focused our molecular analyses on the frontal cortex and hippocampus. Before additional analyses, data were tested for normality using the D'Angostino and Pearson and Shapiro-Wilkes normality tests. Statisitical outliers were detected using Robust regression and Outlier removal (ROUT) with Q set to 1%, and these values were excluded from the analyses (Motulsky and Brown, 2006) . Subject numbers are included in the figure legends.
One mechanism of pioglitazone's beneficial effects after injury is through reducing glial inflammation (Sauerbeck et al., 2011) . We examined expression of protein markers for microglia (allograft inflammatory factor 1; Iba-1) and reactive astroglia (GFAP) in frontal cortex and hippocampus. In frontal cortex, Iba-1 produced a single band at approximately 17 kD (theoretical molecular weight 17 kD) and GFAP produced a single band at 50 kD (theoretical molecular weight 50 kD) (Fig. 3a) . In hippocampus, Iba-1 produced the expected 17 kD band and a second band at approximately 22 kD while GFAP produced the expected 50 kD band as well as a second band at approximately 55kD (Fig. 3d ). In hippocampus, both bands for Iba-1 and GFAP were included in the analysis. There was a moderate effect of treatment on Iba-1 expression in frontal cortex (ω 2 = 0.063). Despite Iba-1 expression in the TBI + pio group being almost double (198%) that of the sham group, these findings were not statistically significant (p = 0.165) (Fig. 3b) . The relative expression of GFAP was 90% that of sham levels in the TBI group and 153% of sham levels in the TBI + pio group, however this reflected only a small effect of treatment (ω 2 = 0.015; p = 0.315) (Fig. 3c ). In the hippocampus, Iba-1 expression in the TBI group was 79% and 82% higher than in the sham and TBI + pio groups, respectively which reflected a moderate effect of TBI, but was not statistically significant (ω 2 = 0.06; p = 0.174) ( Fig. 3e ). There was a large effect of treatment on GFAP expression in hippocampus (ω 2 = 0.17; p = 0.037). GFAP expression was 312% of sham levels in TBI and 406% of sham levels in TBI + pio (Fig. 3f ). Post-hoc analyses identified the TBI + pio group (p = 0.029), but not the TBI group (p = 0.491) as significantly increased above sham GFAP protein levels.
Pioglitazone does not increase expression of PPARγ co-activating protein in chronic TBI
The PPARγ co-activating protein PGC-1a is instrumental in the transcriptional program initiated by PPARγ activation. In both frontal cortex and hippocampus, PGC-1a produced a single band at just over 90 kD (predicted molecular weight 91 kD)( Fig. 4a ). We found no effect of treatment on PGC1a in the frontal cortex (ω 2 = −0.072; p = 0.944) or in hippocampus (ω 2 = −0.070; p = 0.915); PGC1a was expressed at 90% and 99% of sham in TBI and TBI + pio respectively, in frontal cortex (Fig. 4b) , and 100% (TBI) and 89% (TBI + pio) of sham hippocampus ( Fig. 4c ).
Pioglitazone administration increases hexokinase activity but does not affect expression of hexokinase or glucose transporter protein
We examined protein levels of hexokinase and glucose transporter 3 (Glut3). Hexokinase it the initial and rate-limiting step in glucose metabolism while Glut3 is the primary neuronal glucose transporter. In frontal cortex and hippocampus, hexokinase produced a single band at approximately 120 kD (predicted molecular weight 120 kD) and Glut 3 produced a single band at approximately 36 kD (predicted molecular weight 54)( Fig. 5a ). TBI had a moderate effect on cortical expression of hexokinase protein which was,118.5% of sham in TBI and 84.4% of sham in TBI + pio (ω 2 = 0.09; p = 0.101) (Fig. 5b) . In hippocampus, TBI had a smaller effect (ω 2 = 0.03; p = 0.271) on hexokinase protein levels, which were 135% and 165.6% of those found in sham animals in TBI and TBI + pio, respectively (Fig. 5c ). In frontal cortex, Glut3 expression was virtually identical to sham (ω 2 = −0.069; p = 0.969) and 103% and 110% of sham levels in TBI and TBI + pio, respectively (Fig. 5d ). In hippocampus, Glut3 expression in the TBI group was 76% of sham levels and Glut3 expression in the TBI + pio group was 131% of sham levels (Fig. 5e ). While these findings were interesting as Glut3 was the only protein with moderate changes in opposite directions between TBI and TBI + pio, the effect of TBI on Glut3 expression was negligible (ω 2 = 0.004, p = 0.365).
We also tested hexokinase activity, the rate-limiting step for glucose to enter into glycolysis, after pioglitazone treatment in chronic TBI. Our Locomotor activity between sham and TBI groups was not different in chronic animals (tested day 54 after injury) (ω 2 = 0.020, p = 0.302). b. There was a significant effect of treatment on radial arm maze performance (ω 2 = 0.229, p = 0.011). Chronic TBI rats treated with pioglitazone made fewer errors in a radial arm maze working memory task than untreated animals (p = 0.036) and were comparable to sham animals (p = 0.972). n = 10 sham, n = 10 TBI, and n = 9 TBI + pio. Data is mean +/− SEM. * = p < 0.05.
analyses were restricted to the timeframe in which increases in NADH concentration were linear over time. In both cortical and hippocampal samples, the accumulation of NADH began to plateau after 90 min, thus analyses were restricted to the first 90 min of the assay. In frontal cortex, 2 samples, one in the sham group and one in the TBI group were excluded from analysis due to a failure to increase in reaction product over time, leaving n = 9 per group for this assay. Five samples in hippocampus, 2 sham, 2 TBI and one TBI + pio were excluded for the same reason, leaving n = 8 per group for the assay.
In frontal cortex we found a main effect of time (main effect, ω p 2 = 0.82; p < 0.0001) and an interaction of treatment (TBI, TBI + pio, or sham) and time for the accumulation of NADH (interaction, ω p 2 = 0.420; p = 0.007). Post-hoc analysis identified significantly increased NADH concentration in the sham group compared to TBI beginning 60 min after the start of the reaction and thereafter (p < 0.050), and between sham and TBI + pio beginning 80 min after the start of the reaction and thereafter (p < 0.050) (Fig. 5f ). There were no significant differences between the TBI groups in NADH accumulation.
In the hippocampus, there were main effect of treatment (ω p 2 = 0.18; p = 0.042), time (ω p 2 = 0.89; p < 0.0001), and an interaction between treatment and time (ω p 2 = 0.57; p = 0.0001). In this case, NADH concentrations were significantly increased in the TBI + pio group compared to TBI (p < 0.050) beginning 50 min after the start of the assay and thereafter, and between TBI + pio and sham beginning 80 min after the start of the assay and thereafter (p < 0.050) (Fig. 5g ). To verify that the assay was specific for hexokinase activity, we ran pooled samples from TBI and sham with 50 mM of the hexokinase inhibitor, lonidamine. There was no increase in NADH concentration when lonidamine was added to the reaction (data not shown).
Discussion
This is the first study examining the effects of pioglitazone administered in chronic TBI. We found that treating rats with pioglitazone in the late stages of injury, days 46-60 after TBI, alleviated deficits in working memory performance. Contrary to our expectations, these findings did not coincide with increased expression of PGC1a, a transcription coactivator downstream of PPARγ activation that regulates mitochondrial biogenesis. Pioglitazone treatment upregulated PGC1a in vitro (Miglio et al., 2009 ), but we were unable to replicate that finding in vivo in our model. Pioglitazone treatment did not increase protein expression of the neuronal glucose transporter or hexokinase. While there was no change in hexokinase protein itself, we found that hexokinase activity was lower in the frontal cortex of TBI animals than controls. Two weeks of pioglitazone treatment did not alleviate this deficit in frontal cortex, but hexokinase activity in hippocampus was increased in pioglitazone-treated animals.
Working memory deficits after TBI
Deficits in executive function and working memory are common and long-lasting sequelae of TBI in humans (Ciaramelli et al., 2006; Dunning et al., 2016) . Working memory deficits are perhaps one of the most reproducible behavioral findings in pre-clinical TBI models, appearing early after injury (Corser-Jensen et al., 2014; Lyeth et al., 2001) and persisting for months (Lindner et al., 1998) . In rodents, working memory is most often tested using maze-based tasks such as Y-or Tmazes, the Morris water maze, or the radial arm maze, such as we used here. While working memory testing in humans often includes a more complex battery of tests, virtual water mazes, T-mazes, and radial arm mazes are now being used to test working memory dysfunction and Fig. 3 . Pioglitazone effects on glial protein expression. a. Protein levels for GFAP (50 kD) and Iba-1 (17 kD) were probed by Western blot in frontal cortex. The channel for tubulin (50 kD) is turned off so that GFAP is visible. b. Frontal cortex Iba-1 protein levels were similar different between sham, pioglitazone treated or untreated TBI animals (ω 2 = 0.063; p = 0.165). c. In frontal cortex, there was a minimal effect of pioglitazone treatment on protein levels of GFAP (ω 2 = 0.015; p = 0.315). c. In hippocampus GFAP produced 2 bands at 50 kD and 55 kD, and Iba-1 produced the expected 17 kD band and an additional band at 22 KD. d. In hippocampus, there was a moderate effect of TBI on Iba-1 expression (ω 2 = 0.06, p = 0.174). e. In hippocampus there was a significant effect of TBI on GFAP expression (ω 2 = 0.17, p = 0.037). GFAP expression was significantly increased in the pioglitazone treated TBI group relative to sham (p = 0.029). n = 10 sham, n = 9 TBI, and n = 9 TBI + pio in frontal cortex for Iba-1 and GFAP. The dashed line delineates the protein expression level of the sham group. n = 10 sham, n = 10 TBI and n = 8 TBI + pio for iba-1 in hippocampus, and n = 9 sham, n = 9 TBI, and 8 n = TBI + pio for GFAP expression in hippocampus. Data is mean +/− SEM, * = p < 0.05. cognitive decline in human neurobehavioral disorders (Lee et al., 2014) (Goodrich-Hunsaker and Hopkins, 2010) . In our chronic TBI model, we find remarkably consistent deficits in working memory both in the radial arm maze, and in T-maze alternation ( Supplementary Fig. S2) . Tmaze alternation is similarly dependent on cortical and hippocampal circuits to the radial arm maze task (Hoskison et al., 2009; Yang and Mailman, 2018; Deacon and Rawlins, 2006) , providing further evidence for a consistent underlying defect.
Hippocampal glucose metabolism and cognition
Cognitive exertion increases brain glucose uptake (Madsen et al., 1995) which in turn supports acute changes in neuronal signaling (Patel et al., 2004) . Neural activity is so tightly linked to metabolism, it is the basis for functional neuroimaging such as functional MRI or positron emission tomography (PET imaging) (Patel et al., 2004; Hyder and Rothman, 2012) . Ultimately, however, neural activity is reflected in behavioral output. In humans and rodents, manipulating the availability of energetic substrates alters performance on tests of executive function and working memory (Moro et al., 2011) . Glucose infused directly into the hippocampus improves working memory performance in the Y-and Tmaze alternation tasks (Ragozzino et al., 1998; Ragozzino et al., 1996; McNay et al., 2006; Krebs and Parent, 2005) , and strengthens consolidation of associative learning (Krebs and Parent, 2005) .
Pioglitazone treatment increased hexokinase activity in hippocampus but not frontal cortex, although both regions contribute to radial arm maze task performance (Kolb et al., 1983; Astur et al., 2005) . While this is consistent with the above-mentioned studies in which increased glucose availability in hippocampus improved working memory, the divergence in the cortical and hippocampal response to injury and to pioglitazone treatment is interesting and worthy of further study.
Our expectation was that hexokinase activity would be more impaired after TBI in hippocampus rather than in cortex due to its proximity to the location of the injury. While we found reduced hexokinase activity in the frontal cortex of TBI animals. However, in hippocampus hexokinase activity was very similar between untreated TBI and sham, but was increased above both TBI and sham groups in pioglitazone-treated TBI animals. Upregulation of hexokinase activity in the hippocampus was not dependent on upregulation of hexokinase or the neuronal glucose transporter, indicating that the availability of these proteins was neither the primary obstacle to glucose metabolism in injured hippocampus, nor the source of the increased hexokinase activity.
However, it may be that the hippocampus is, in fact, more damaged and impaired than cortex. While we anticipated a global decline in energy metabolism in hippocampus, hyperglycolytic activity in a subpopulation of cells, speculatively microglia, could coincide with depressed glucose metabolism in other cell populations. In tissue homogenate, such as we used here, the result would be an intermediate level of hexokinase activity in the prepared sample. Boosting glucose metabolism in metabolically depressed cells, without mitigating excess activity in hyperglycolytic cells would then result in samples with enzyme activity higher than controls. Lactate levels in hippocampus remained elevated 60 days after TBI (McGuire et al., 2018) providing some evidence in support of a hyperglycolytic population of cells in hippocampus, but this remains to be tested.
Pioglitazone in neurodegenerative conditions
We hypothesize that chronic injury produces a metabolic state very similar to chronic neurodegenerative disorders associated with aging. Pioglitazone effectively ameliorated behavioral deficits in other models of chronic neurodegenerative disorders in rodents (Breidert et al., 2002; Gupta and Gupta, 2012) and non-human primates (Swanson et al., 2011) . Treatment with pioglitazone improved cognitive outcomes in models of Alzheimer's disease (AD) (Gupta and Gupta, 2012) , Parkinson's disease (Swanson et al., 2011) , chronic alcohol use (Cippitelli et al., 2017) , type II diabetes (Gao et al., 2017) and acute TBI (Sauerbeck et al., 2011) . The mechanisms by which pioglitazone provides these benefits remain uncertain. Pioglitazone upregulates glucose consumption and glycolytic efficiency in peripheral tissues (Meneses et al., 2016; Bajaj et al., 2003) , however, the data is less conclusive in CNS. Pioglitazone upregulates brain glucose consumption in vivo (Dello Russo et al., 2003; Nicolakakis et al., 2008) in some studies, however other studies in similar models failed to replicate these findings (Izawa et al., 2009; Galea et al., 2006) .
Damaging inflammation and astrogliosis is a nearly universal Fig. 4 . Pioglitazone treatment did not increase expression of PPARγ co-activating protein. a. PGC1a produced a single band at 91 kD in both frontal cortex and hippocampus tissue. Expression of the PPARγ co-activating protein PGC1a was not altered by pioglitazone treatment in (b) frontal cortex (ω 2 = −0.072, p = 0.944) or (c) hippocampus (ω 2 = −0.070, p = 0.915). The dashed line delineates the protein expression level of the sham group. n = 10 sham, n = 10 TBI, and n = 8 TBI + pio in frontal cortex. n = 10 sham, n = 9 TBI and n = 9 TBI + pio in hippocampus. Data is mean +/− SEM.
feature of neurodegenerative conditions, including TBI. However, in our studies, pioglitazone treatment did not reduce expression of GFAP.
In fact, TBI animals that received pioglitazone showed increased GFAP expression in the hippocampus. However, while expression of GFAP is a characteristic marker of inflamed astroglia, it provides no additional insight into the molecular phenotype of GFAP-expressing astrocytes (Iglesias et al., 2017) . It is becoming increasingly clear that there is considerable regional and temporal heterogeneity within populations of reactive astrocytes (Yeh et al., 2009; Daginakatte et al., 2008; Peng et al., 2013; Zamanian et al., 2012) . Virtually all previous studies investigating the anti-inflammatory effects of pioglitazone in injury, experimental autoimmune encephalitis, and Parkinson's disease initiated treatment during acute stages of inflammation (Sauerbeck et al., 2011; Breidert et al., 2002; Chedrawe et al., 2018) . In all of these studies, pioglitazone helped alleviate expression of inflammatory cytokines, decreased cell death, and improved behavioral responses. It may be that pioglitazone is more effective at limiting the initial inflammatory response than reversing chronic inflammation, or that the duration of treatment used here was too short to produce a noticeable difference in these studies. It will be of great interest going forward to determine whether pioglitazone and similar drugs act through modulating the molecular and metabolic phenotype of GFAP-expressing "reactive" astrocytes.
Limitations of the current study
There are a number of limitations to the current study. We tested a single dosing strategy of pioglitazone. In the neurodegeneration Fig. 5 . Pioglitazone effects on glycolytic protein expression and hexokinase activity. a. Hexokinase produced a single band at 120 kD in both frontal cortex and hippocampus. Glut 3 produced a single band at approximately 36 kD. b. In frontal cortex there was a moderate effect of TBI on hexokinase expression (ω 2 = 0.090, p = 0.101) that was not significant. c. there was a smaller, also non-significant, effect of TBI on hexokinase expression in hippocampus (ω 2 = 0.030, p = 0.271). d There was no effect of treatment on Glut3 expression in frontal cortex (ω 2 = −0.069, p = 0.969) or (e) in hippocampus (ω 2 = 0.004, p = 0.365). f. In frontal cortex, hexokinase activity was decreased relative to sham in both TBI groups and was not altered by pioglitazone treatment. g. In hippocampus, pioglitazone increased hexokinase activity in treated TBI rats above both untreated TBI rats and controls. The dashed line delineates the protein expression level of the sham group. Hexokinase protein in frontal cortex and hippocampus n = 10 sham, n = 10 TBI, n = 9 TBI + pio. Glut3: n = 10 sham, n = 10 TBI, n = 9 TBI + pio in frontal cortex and n = 9 sham, n = 10 TBI, and n = 9 TBI + pio in hippocampus. Hexokinase activity n = 9 per group in frontal cortex, n = 8 per group in hippocampus. Data is mean +/− SEM. * = p < 0.05 between TBI-and sham (f) or TBI-and TBI+ (g). ★ = p < 0.05 between TBI+ and sham (f and g). literature, oral doses in rodents range from < 1 mg/kg/day-60 mg/kg/ day with treatment durations between 1 and 8 weeks (Grommes et al., 2013; Cippitelli et al., 2017; Breidert et al., 2002; Gupta and Gupta, 2012; Nicolakakis et al., 2008; Kaur et al., 2009; Kalonia et al., 2010) . We selected a single dose and a relatively short duration from within that range for the current studies. In some studies, higher doses of pioglitazone were less effective than lower doses (Culman et al., 2012; Crenshaw et al., 2015) , and additional work will be required to determine an optimal dose range and timeframe for administration.
Our animals showed large intragroup variability in some measures. Over the 8 weeks of recovery, we expect that the trajectories of individual rats would be different. As we currently do not know or understand all of the factors that contribute to disability or recovery after TBI, it is difficult to know whether we have effectively controlled for all of the critical variables. Our animals received a standard diet and did not show significant differences in weight gain, however other potentially relevant parameters, such as plasma lipid levels, systolic blood pressure, and blood glucose, were not measured.
As noted before, these studies utilized tissue homogenate, and we are unable to differentiate the contributions of specific cells types or subpopulations to the resulting data. This means we are unable to identify divergent phenotypes with populations of cells within the tissue, as we suspect may have occurred in the hippocampus, or could be missing relevant changes occurring within small groups of cells. The limitations of our tissue preparation precludes detailed spatial discrimination within this same cohort of animals and future studies will begin to address questions of cell specificity. Immunohistochemistry for Iba-1 and GFAP will provide additional insight into the morphology and distribution of glia in these tissues. Distinctive mitochondrial deficits persist for at least a month after cortical impact injury (Lyons et al., 2018) , and determining whether similar mitochondrial damage exists in our chronic injury model and whether pioglitazone or other PPAR agonists are able to remediate those defects is a top priority for future work.
Finally, there are novel actions of pioglitazone that we did not explore, such as reduced synaptic loss via CDK5 inhibition (Chen et al., 2015) , inhibition of protein oligimerization (Hamano et al., 2016) , and modulation of neuronal excitability (Hung et al., 2019) . These effects of pioglitazone are relatively recently described, and warrant further investigation, particularly in chronic injury.
Conclusions
There are millions of people in the United States living with chronic symptoms of TBI (Stocchetti and Zanier, 2016) , and treatment options are limited. The majority of the efforts to develop effective therapeutics for TBI have focused on early treatment and prevention of long-term symptoms. In these studies, we used a model of chronic injury to determine whether the FDA-approved drug pioglitazone would increase glucose metabolism in brain regions critical to cognitive function and whether this would improve working memory performance in treated animals. Our findings suggest that providing metabolic support to the brain may be a strategy to reduce cognitive symptoms after injury. More importantly, our findings indicate that the treatment window for post-TBI symptoms does not close within the first few days after injury.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.nbd.2019.104611.
